美國Biolog  www.biolog.com
美國Biolog公司致力于微生物鑒定領域新技術新產(chǎn)品的開發(fā)、生產(chǎn)和銷售，是全球高新技術百強之一，其獨創(chuàng)的碳源利
用方法已獲美國FDA認可。Biolog鑒定系統(tǒng)可鑒定包括細菌、酵母和真菌在內(nèi)約2000種微生物，便于各領域的微生物實驗室用于對微生物的鑒定；另外，Biolog的智能軟件和獨特的設計理念又使其特別適用于生態(tài)研究領域。

Biolog, Inc. is a privately held company that began operations in 1984. The company's product lines have been built upon patented technology that greatly simplifies testing of cells. Biolog's first products were introduced in 1988 and by 1990 it had established a profitable growing business in microbiology for the identification and characterization of microbial cells. In 1991, Biolog, Inc. was a recipient of the "R&D 100 Award" for the company's groundbreaking bacterial identification products. These products, marketed under the MicroLog™, MicroStation™ and OmniLog® brand names, are sold worldwide through direct sales as well as distribution. The principal customers of our microbiology identification products are laboratories needing state-of-the-art capabilities, especially pharmaceutical, biotech, cosmetics, and medical device companies, university and government research laboratories, labs testing for diseases in animals and plants, labs performing environmental monitoring, and companies or organizations involved in production or testing of food and drink.
From this technology base in 1999 and with an SBIR award from the National Institutes for Health Human Genome Research Institute, Biolog began development of its revolutionary Phenotype MicroArray™ technology. This groundbreaking technology allows researchers to evaluate thousands of cellular phenotypes simultaneously in both microbial and mammalian cells. Development of array sets testing 2,000 phenotypes of microbial cells was completed and first introduced in September 2001. Now Phenotype MicroArray technology is being tested under license in many pharmaceutical and biotechnology companies for use in drug and enzyme development programs. Biolog continues to develop and patent unique and proprietary technologies that allow scientists to broadly characterize cellular functions using arrays of phenotypic tests.
In addition to revenue from product sales, Biolog has received funding from private investments and Small Business Innovation Research (SBIR) grants and contracts from the National Institutes for Health (NIH), Department of Energy (DOE), National Aeronautics and Space Administration (NASA) and the National Science Foundation (NSF).